AP3412A - Targeting pax2 for the treatment of breast cancer - Google Patents

Targeting pax2 for the treatment of breast cancer

Info

Publication number
AP3412A
AP3412A AP2012006181A AP2012006181A AP3412A AP 3412 A AP3412 A AP 3412A AP 2012006181 A AP2012006181 A AP 2012006181A AP 2012006181 A AP2012006181 A AP 2012006181A AP 3412 A AP3412 A AP 3412A
Authority
AP
ARIPO
Prior art keywords
treatment
breast cancer
targeting pax2
pax2
targeting
Prior art date
Application number
AP2012006181A
Other languages
English (en)
Other versions
AP2012006181A0 (en
Inventor
Carlton D Donald
Original Assignee
Phigenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/546,292 external-priority patent/US20100029504A1/en
Priority claimed from US12/708,294 external-priority patent/US8080534B2/en
Application filed by Phigenix Inc filed Critical Phigenix Inc
Publication of AP2012006181A0 publication Critical patent/AP2012006181A0/xx
Application granted granted Critical
Publication of AP3412A publication Critical patent/AP3412A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AP2012006181A 2009-08-24 2010-02-19 Targeting pax2 for the treatment of breast cancer AP3412A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/546,292 US20100029504A1 (en) 2007-01-16 2009-08-24 Detecting pax2 for the diagnosis of breast cancer
US12/708,294 US8080534B2 (en) 2005-10-14 2010-02-18 Targeting PAX2 for the treatment of breast cancer
PCT/US2010/024740 WO2011025556A1 (fr) 2009-08-24 2010-02-19 Ciblage de pax2 pour le traitement du cancer du sein

Publications (2)

Publication Number Publication Date
AP2012006181A0 AP2012006181A0 (en) 2012-04-30
AP3412A true AP3412A (en) 2015-09-30

Family

ID=43628306

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006181A AP3412A (en) 2009-08-24 2010-02-19 Targeting pax2 for the treatment of breast cancer

Country Status (11)

Country Link
EP (2) EP2470217B1 (fr)
JP (1) JP2013503162A (fr)
CN (2) CN104083772A (fr)
AP (1) AP3412A (fr)
AU (1) AU2010286924B2 (fr)
CA (1) CA2772036A1 (fr)
IL (1) IL218286A (fr)
NZ (1) NZ599005A (fr)
RU (2) RU2016133412A (fr)
WO (1) WO2011025556A1 (fr)
ZA (1) ZA201202169B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104628864B (zh) * 2013-11-14 2020-04-10 中国医学科学院医药生物技术研究所 一种抗肿瘤融合蛋白EL-defensin、其编码基因和用途
CN108484765B (zh) * 2018-04-28 2020-08-25 浙江大学 一种抗人α-防御素-1单克隆抗体及其应用
CN109908326A (zh) * 2018-09-14 2019-06-21 上海众择生物科技有限公司 人β-防御素1在促进NK细胞杀伤活性中的应用
MX2023004899A (es) 2020-10-28 2023-07-18 Baylor College Medicine Direccionamiento de src-3 en celulas inmunitarias como un inmunomodulador terapeutico para el tratamiento de cancer.
CN112646895A (zh) * 2021-01-22 2021-04-13 深圳科诺医学检验实验室 检测基因表达量的引物、探针、试剂盒、检测方法及应用
CN115724966A (zh) * 2022-08-22 2023-03-03 北京中杉金桥生物技术有限公司 一种抗人配对盒基因2兔单克隆抗体、制备方法及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA2172955C (fr) * 1993-10-25 2002-12-24 Andrew S. Janoff Defensines liposomiques
CA2400874A1 (fr) * 2000-02-25 2001-08-30 The Regents Of The University Of California Therapie dirigee sur le recepteur membranaire des oestrogenes, dans le cancer du sein
WO2002026236A1 (fr) * 2000-09-28 2002-04-04 Virginia Commonwealth University Elimination de cellules tumorales par suppression du point de controle de cycle combine a l'inhibition du trajet classique de proteine kinase activee par mitogene
CZ308053B6 (cs) 2000-12-01 2019-11-27 Max Planck Gesellschaft Izolovaná molekula dvouřetězcové RNA, způsob její výroby a její použití
SE0401302D0 (sv) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Inhibition of erk-phosphorylation
US20080081791A1 (en) * 2006-07-06 2008-04-03 Weida Huang Methods of using combinations of siRNAs for treating a disease or a disorder, and for enhancing siRNA efficacy in RNAi
WO2008060899A2 (fr) * 2006-11-09 2008-05-22 Ore Pharmaceuticals Inc. Procédés de dépistage et de traitement du cancer du sein
CA2669318A1 (fr) * 2006-11-09 2008-05-22 The Regents Of The University Of Michigan Diagnostic et traitement du cancer du sein
AU2008206258B2 (en) * 2007-01-16 2013-06-13 Musc Foundation For Research Development Compositions and methods for diagnosing, treating, and preventing prostate conditions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bose, SK et al (2009) Molecular Immunology v46 pp1140-1148 *
HURTADO, A. ET AL.: "Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen.", NATURE., vol. 456, 4 December 2008 (2008-12-04), pages 663 - 666 *
MURATOVSKA, A. ET AL.: "Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival.", ONCOGENE, vol. 22, 2003, pages 7989 - 7997 *

Also Published As

Publication number Publication date
JP2013503162A (ja) 2013-01-31
CN104083772A (zh) 2014-10-08
RU2016133412A3 (fr) 2018-12-10
EP2470217A4 (fr) 2012-08-15
IL218286A0 (en) 2012-07-31
WO2011025556A1 (fr) 2011-03-03
ZA201202169B (en) 2013-05-29
AU2010286924A1 (en) 2012-04-19
RU2016133412A (ru) 2018-12-10
AP2012006181A0 (en) 2012-04-30
CN102481379A (zh) 2012-05-30
RU2012111271A (ru) 2013-10-10
EP2470217A1 (fr) 2012-07-04
EP2470217B1 (fr) 2020-10-07
NZ599005A (en) 2014-11-28
AU2010286924B2 (en) 2012-08-09
IL218286A (en) 2017-11-30
EP3811950A1 (fr) 2021-04-28
CA2772036A1 (fr) 2011-03-03

Similar Documents

Publication Publication Date Title
IL218575A0 (en) Treatment of cancer
IL243741A0 (en) Anti-angiogenic therapy for the treatment of breast cancer
HK1175476A1 (en) Cancer treatment
IL219073A (en) A drug combination for cancer treatment
PL2482849T3 (pl) Skojarzona immunoterapia w leczeniu nowotworu
IL217291A0 (en) Exosome based treatment of cancer
IL215108A0 (en) Amatoxin-armed target-binding moieties for the treatment of cancer
SG10201508495VA (en) Combination treatment of cancer
IL213761A0 (en) Novel ortho-aminoamides for the treatment of cancer
ZA201300218B (en) Treatment of blood cancer
EP2461814A4 (fr) Traitement du cancer de la prostate
ZA201108118B (en) Treatment regimin utilizing neratinib for breast cancer
HRP20181757T1 (hr) Kombinirana terapija za liječenje raka dojke
ZA201300762B (en) Novel combination therapy for the treatment of cancer
ZA201202169B (en) Targeting pax2 for the treatment of breast cancer
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
EP2403341A4 (fr) Traitement d'un cancer du poumon
GB0916686D0 (en) Treatment of cancer
EP2477632A4 (fr) Combinaison pharmaceutique pour traiter une tumeur
GB0906490D0 (en) Use of tetanolic for treatment of breast cancer
GB0921757D0 (en) Treatment of cancer
GB201017356D0 (en) Combination treatment of cancer
TH0901005197A (th) การบำบัดต้านการเจริญเติบโตของเส้นโลหิตสำหรับการรักษาของโรคมะเร็งเต้านม
GB0921102D0 (en) Cancer Therapy
GB0913603D0 (en) Cancer therapy